- ECYT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.1 million.
- ECYT traded 161,281 shares today in the pre-market hours as of 8:17 AM, representing 10.9% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ECYT with the Ticky from Trade-Ideas. See the FREE profile for ECYT NOW at Trade-Ideas More details on ECYT: Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. ECYT has a PE ratio of 22.8. Currently there are 5 analysts that rate Endocyte a buy, no analysts rate it a sell, and 3 rate it a hold. The average volume for Endocyte has been 1.2 million shares per day over the past 30 days. Endocyte has a market cap of $293.8 million and is part of the health care sector and drugs industry. The stock has a beta of 0.78 and a short float of 20.2% with 4.63 days to cover. Shares are down 30.1% year-to-date as of the close of trading on Thursday.